Articles related to GLP-1 RECEPTOR AGONISTS

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.

Rodent and non-human primate studies showed glucagon and GIP agonism alone produced weight loss comparable to GLP-1-containing triple agonists in a Bluewater Biosciences-funded program.

As GLP‑1 medications become widely used for obesity and metabolic disease, clinicians are confronting a growing question: What should be done when patients don’t respond as expected?

“Semaglutide and, to a lesser extent, liraglutide were associated with significantly lower risk of worsening mental illness.” – Lead Study Researcher Heidi Taipale, PhD, University of Eastern Finland and Niuvanniemi Hospital

“In this observational study, women who used menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” says Maria Daniela Hurtado Andrade, M.D., Ph.D., endocrinologist at Mayo Clinic and senior author of the study.